<DOC>
	<DOCNO>NCT03104478</DOCNO>
	<brief_summary>The trial enroll 194 previously untreated DLBCL patient 20 month , objective send local investigator extensive molecular tumor characterization D38 least 80 % enrolled patient . The feasibility efficiency demonstrate deploy operate nation-wide network dedicate multidisciplinary platform .</brief_summary>
	<brief_title>Real Time Molecular Characterization Diffuse Large B Cell Lymphoma ( DLBCL )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<criteria>DLBCL patient eligible frontline treatment combination anthracyclinebased chemotherapy plus antiCD20 monoclonal antibody , Rituximab : RCHOP 14 , RCHOP 21 , R miniCHOP , RACVBP , RCOPADEM . Patients treat RCHOP associate experimental drug ( ( polatuzumab , tazemetostat , venetoclax , entospletinib , lenalidomide , ibrutinib , anti PD1/anti PDL1 … . ) A short corticotherapy ( prednisone , maximum 7 day ) give prephase therapy allow . Eligible histological subtypes : particular DLBCL NOS , PMBL , high grade Bcell lymphoma ( HGBCL ) withMYC BCL2 and/or BCL6 rearrangement , HGBCL NOSFL grade 3B untreated transform low grade NHL . ≥ 18 year old , IPI = 05 With available tumor Biopsy ( FFPE ) send RT3 platform time inclusion ( say inclusion late ) . Patient underwent needle core biopsy sample exclude sufficient material available molecular histopathological exploration No available FFPE biopsy material insufficient quality/quantity tumor sample accord prerequisite No sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>DLBCL</keyword>
	<keyword>Real time molecular characterization</keyword>
</DOC>